IA
HRMY icon

IFP Advisors’s Harmony Biosciences HRMY Stock Holding History

IFP Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
8,102
+353
+5% +$11.1K 0.01% 1296
2026
Q1 		$217K Buy
7,749
+330
+4% +$10.8K ﹤0.01% 1349
2025
Q4 		$278K Buy
7,419
+926
+14% +$30.4K 0.01% 1203
2025
Q3 		$179K Sell
6,493
-193
-3% -$6.65K ﹤0.01% 1342
2025
Q2 		$211K Buy
6,686
+2,080
+45% +$66.9K 0.01% 1250
2025
Q1 		$153K Buy
4,606
+4,600
+76,667% +$165K ﹤0.01% 1302
2024
Q4 		$206 Buy
+6
New +$206 ﹤0.01% 3727
2023
Q4 		– Sell
-25
Closed -$819 – 3187
2023
Q3 		$819 Hold
25
– – ﹤0.01% 3039
2023
Q2 		$880 Hold
25
– – ﹤0.01% 3107
2023
Q1 		$925 Sell
25
-363
-94% -$16.5K ﹤0.01% 3093
2022
Q4 		$21K Sell
388
-611
-61% -$33.6K ﹤0.01% 2847
2022
Q3 		$45K Buy
999
+332
+50% +$16.2K ﹤0.01% 2445
2022
Q2 		$32K Hold
667
– – ﹤0.01% 2481
2022
Q1 		$32K Buy
+667
New +$27.2K ﹤0.01% 2481

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's HRMY Position: Q2 2026 in Review

IFP Advisors increased its Harmony Biosciences (HRMY) stake by 4.6% in Q2 2026, buying an estimated $11.1K and bringing the position to 8,102 shares worth $295K. The position accounts for 0.01% of the portfolio, ranked #1296.

IFP Advisors first reported a position in HRMY in Q1 2022 and has held it in 14 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • IFP Advisors held 8,102 shares of Harmony Biosciences worth $295K as of Q2 2026.
  • IFP Advisors bought 353 Harmony Biosciences shares in Q2 2026, an estimated $11.1K.
  • Harmony Biosciences made up 0.01% of IFP Advisors's portfolio in Q2 2026, its #1296 holding.
  • IFP Advisors first reported a position in Harmony Biosciences in Q1 2022 and has held it in 14 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.